Giacomo Iovane1,*, Luca Traman2, Michele Maffezzoli1,3, Giuseppe Fornarini2, Domenico Corradi4, Debora Guareschi4, Matteo Santoni5,#, Sebastiano Buti1,#
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070523
- 30 December 2025
Abstract Background: While the treatment of metastatic renal cell carcinoma (mRCC) is evolving due to immune checkpoint inhibitors (ICIs), optimal strategies for later lines of therapy have yet to be defined. The combination of lenvatinib and everolimus represents a viable option, and the present review aimed to summarize its activity, effectiveness, and safety. Methods: A systematic review of the literature was conducted using PubMed, targeting studies published between 2018 and 2025. Eligible studies included English-language prospective and retrospective trials reporting survival outcomes in mRCC patients treated with lenvatinib and everolimus after at least one ICI-containing regimen. Results:… More >
Graphic Abstract